#United States #Stony Brook #ZBeats #ZBPro #ECG Analysis

ZBeats Gains FDA Clearance for ZBPro Diagnostic v2.0

In a significant advancement for wearable health technology, ZBeats Inc. has received FDA 510(k) clearance for its ZBPro Diagnostic v2.0. This innovative platform is designed to enhance ECG analysis by supporting recordings that range from a brief one minute to an extended 14 days. This flexibility positions ZBPro v2.0 as a powerful tool for both clinical and consumer health applications.

Key Features of ZBPro Diagnostic v2.0

The upgraded ZBPro Diagnostic platform is tailored to accommodate various recording technologies, including Holter configurations and wearable patches. As part of their commitment to improving healthcare analytics, ZBeats has incorporated robust features like NoiseGuard and a unified intelligence layer that efficiently transforms data into a useful clinical context.

According to Bin Fang, PhD, the CEO and co-founder of ZBeats, this platform exemplifies the company's vision for independent ECG intelligence and addresses the need for high-quality, scalable analysis of electrocardiographic data. By decoupling ECG intelligence from specific hardware setups, ZBPro enhances adaptability across clinical research, monitoring operations, and consumer-grade wearables.

Enhanced Clinical Workflow

ZBPro Diagnostic v2.0 offers automated retrospective beat and rhythm analysis that include detecting conditions such as atrial fibrillation. Coupled with integrated review, editing, and reporting functionalities, the platform manifests an intuitive technician interface that streamlines operational workflows. The system’s design allows clinical teams to standardize their processes and move studies from initial analysis to final reporting more efficiently. This optimizes operational capacities, especially for high-volume Independent Diagnostic Testing Facilities (IDTFs).

Showcase at HRX Live 2026

ZBeats is set to showcase the new ZBPro v2.0 at the upcoming HRX Live 2026 event in Atlanta, Georgia, scheduled from September 18-20. Attendees will have the opportunity to experience the platform firsthand, explore its capabilities, and engage with the ZBeats executive team for discussions on future innovations and applications.

The HRX conference stands as a prominent platform for healthcare technology, making it an ideal venue for ZBeats to unveil their advancements in ECG technologies. Event attendees can visit HRX Live 2026 for detailed information on the event and the innovations on display.

About ZBeats Inc.

Established in 2019 and headquartered in Stony Brook, New York, ZBeats Inc. is a pioneering entity in medical technology, focusing on independent, cloud-native ECG intelligence solutions. The company specializes in device-agnostic software that transforms raw electrocardiographic data into structured clinical intelligence, thus boosting operational efficiency within healthcare networks. Their FDA-cleared flagship platform, ZBPro Diagnostic, combines AI-driven analysis with advanced review and reporting tools, marking a substantial leap in clinical research and care delivery.

For further details regarding ZBeats’ offerings, visit their official website at zbeats.co.